

1648



1600
#15
109

RAW SEQUENCE LISTING

DATE: 01/17/2003

PATENT APPLICATION: US/09/641,528A

TIME: 10:57:53

Input Set : N:\Crf4\01162003\I641528.raw

Output Set: N:\CRF4\01172003\I641528A.raw

RECEIVED

JAN 21 2003

TECH CENTER 1600/2900

1 <110> APPLICANT: Sette, Alessandro
 2 Sidney, John
 3 Southwood, Scott
 4 Chesnut, Robert
 5 Celis, Esteban
 6 Grey, Howard
 7 <120> TITLE OF INVENTION: INDUCING CELLULAR IMMUNE RESPONSES TO HUMAN PAPILLOMAVIRUS
 8 USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS
 9 <130> FILE REFERENCE: 2060.0100001
 10 <140> CURRENT APPLICATION NUMBER: US/09/641,528A
 11 <141> CURRENT FILING DATE: 2000-08-15
 12 <150> PRIOR APPLICATION NUMBER: US 60/172,705
 13 <151> PRIOR FILING DATE: 1999-12-10
 14 <160> NUMBER OF SEQ ID NOS: 51504
 15 <170> SOFTWARE: FastSEQ for Windows Version 4.0
 17 <210> SEQ ID NO: 1
 18 <211> LENGTH: 10
 19 <212> TYPE: PRT
 20 <213> ORGANISM: Artificial Sequence
 21 <220> FEATURE:
 22 <223> OTHER INFORMATION: Peptide Derived from Human Papillomavirus
 23 <400> SEQUENCE: 1
 24 Ala Met Leu Ala Lys Phe Lys Glu Leu Tyr
 25 1 5 10
 27 <210> SEQ ID NO: 2
 28 <211> LENGTH: 8
 29 <212> TYPE: PRT
 30 <213> ORGANISM: Artificial Sequence
 31 <220> FEATURE:
 32 <223> OTHER INFORMATION: Peptide Derived from Human Papillomavirus
 33 <400> SEQUENCE: 2
 34 Ala Thr Val Pro Cys Trp Asn Tyr
 35 1 5
 37 <210> SEQ ID NO: 3
 38 <211> LENGTH: 9
 39 <212> TYPE: PRT
 40 <213> ORGANISM: Artificial Sequence
 41 <220> FEATURE:
 42 <223> OTHER INFORMATION: Peptide Derived from Human Papillomavirus
 43 <400> SEQUENCE: 3
 44 Ala Val Gln Val Leu Lys Arg Lys Tyr
 45 1 5
 47 <210> SEQ ID NO: 4

P-6
ENTERED

RAW SEQUENCE LISTING

DATE: 01/17/2003

PATENT APPLICATION: US/09/641,528A

TIME: 10:57:53

Input Set : N:\Crf4\01162003\I641528.raw

Output Set: N:\CRF4\01172003\I641528A.raw

48 <211> LENGTH: 11
49 <212> TYPE: PRT
50 <213> ORGANISM: Artificial Sequence
51 <220> FEATURE:
52 <223> OTHER INFORMATION: Peptide Derived from Human Papillomavirus
53 <400> SEQUENCE: 4
54 Cys Thr Phe Glu Leu Ser Gln Met Val Gln Trp
55 1 5 10
57 <210> SEQ ID NO: 5
58 <211> LENGTH: 10
59 <212> TYPE: PRT
60 <213> ORGANISM: Artificial Sequence
61 <220> FEATURE:
62 <223> OTHER INFORMATION: Peptide Derived from Human Papillomavirus
63 <400> SEQUENCE: 5
64 Asp Ile Val Asp Asp Ser Glu Ile Ala Tyr
65 1 5 10
67 <210> SEQ ID NO: 6
68 <211> LENGTH: 11
69 <212> TYPE: PRT
70 <213> ORGANISM: Artificial Sequence
71 <220> FEATURE:
72 <223> OTHER INFORMATION: Peptide Derived from Human Papillomavirus
73 <400> SEQUENCE: 6
74 Asp Ser Asp Thr Gly Glu Asp Leu Val Asp Phe
75 1 5 10
77 <210> SEQ ID NO: 7
78 <211> LENGTH: 8
79 <212> TYPE: PRT
80 <213> ORGANISM: Artificial Sequence
81 <220> FEATURE:
82 <223> OTHER INFORMATION: Peptide Derived from Human Papillomavirus
83 <400> SEQUENCE: 7
84 Asp Ser Glu Ile Ala Tyr Lys Tyr
85 1 5
87 <210> SEQ ID NO: 8
88 <211> LENGTH: 10
89 <212> TYPE: PRT
90 <213> ORGANISM: Artificial Sequence
91 <220> FEATURE:
92 <223> OTHER INFORMATION: Peptide Derived from Human Papillomavirus
93 <400> SEQUENCE: 8
94 Asp Ser Ile Lys Thr Leu Leu Gln Gln Tyr
95 1 5 10
97 <210> SEQ ID NO: 9
98 <211> LENGTH: 9
99 <212> TYPE: PRT
100 <213> ORGANISM: Artificial Sequence
101 <220> FEATURE:

RAW SEQUENCE LISTING

DATE: 01/17/2003

PATENT APPLICATION: US/09/641,528A

TIME: 10:57:53

Input Set : N:\Crf4\01162003\I641528.raw

Output Set: N:\CRF4\01172003\I641528A.raw

```

102 <223> OTHER INFORMATION: Peptide Derived from Human Papillomavirus
103 <400> SEQUENCE: 9
104     Asp Thr Gly Glu Asp Leu Val Asp Phe
105         1             5
107 <210> SEQ ID NO: 10
108 <211> LENGTH: 9
109 <212> TYPE: PRT
110 <213> ORGANISM: Artificial Sequence
111 <220> FEATURE:
112 <223> OTHER INFORMATION: Peptide Derived from Human Papillomavirus
113 <400> SEQUENCE: 10
114     Asp Thr Asn Ser Asn Ala Ser Ala Phe
115         1             5
117 <210> SEQ ID NO: 11
118 <211> LENGTH: 10
119 <212> TYPE: PRT
120 <213> ORGANISM: Artificial Sequence
121 <220> FEATURE:
122 <223> OTHER INFORMATION: Peptide Derived from Human Papillomavirus
123 <400> SEQUENCE: 11
124     Glu Leu Asn Asp Lys Asn Trp Lys Ser Phe
125         1             5             10
127 <210> SEQ ID NO: 12
128 <211> LENGTH: 11
129 <212> TYPE: PRT
130 <213> ORGANISM: Artificial Sequence
131 <220> FEATURE:
132 <223> OTHER INFORMATION: Peptide Derived from Human Papillomavirus
133 <400> SEQUENCE: 12
134     Glu Leu Asn Asp Lys Asn Trp Lys Ser Phe Phe
135         1             5             10
137 <210> SEQ ID NO: 13
138 <211> LENGTH: 8
139 <212> TYPE: PRT
140 <213> ORGANISM: Artificial Sequence
141 <220> FEATURE:
142 <223> OTHER INFORMATION: Peptide Derived from Human Papillomavirus
143 <400> SEQUENCE: 13
144     Glu Leu Ser Gln Met Val Gln Trp
145         1             5
147 <210> SEQ ID NO: 14
148 <211> LENGTH: 10
149 <212> TYPE: PRT
150 <213> ORGANISM: Artificial Sequence
151 <220> FEATURE:
152 <223> OTHER INFORMATION: Peptide Derived from Human Papillomavirus
153 <400> SEQUENCE: 14
154     Glu Leu Ser Gln Met Val Gln Trp Ala Tyr
155         1             5             10

```

RAW SEQUENCE LISTING

DATE: 01/17/2003

PATENT APPLICATION: US/09/641,528A

TIME: 10:57:53

Input Set : N:\Crf4\01162003\I641528.raw

Output Set: N:\CRF4\01172003\I641528A.raw

157 <210> SEQ ID NO: 15
158 <211> LENGTH: 9
159 <212> TYPE: PRT
160 <213> ORGANISM: Artificial Sequence
161 <220> FEATURE:
162 <223> OTHER INFORMATION: Peptide Derived from Human Papillomavirus
163 <400> SEQUENCE: 15
164 Glu Thr Glu Thr Ala His Ala Leu Phe
165 1 5
167 <210> SEQ ID NO: 16
168 <211> LENGTH: 9
169 <212> TYPE: PRT
170 <213> ORGANISM: Artificial Sequence
171 <220> FEATURE:
172 <223> OTHER INFORMATION: Peptide Derived from Human Papillomavirus
173 <400> SEQUENCE: 16
174 Glu Thr Glu Thr Pro Cys Ser Gln Tyr
175 1 5
177 <210> SEQ ID NO: 17
178 <211> LENGTH: 9
179 <212> TYPE: PRT
180 <213> ORGANISM: Artificial Sequence
181 <220> FEATURE:
182 <223> OTHER INFORMATION: Peptide Derived from Human Papillomavirus
183 <400> SEQUENCE: 17
184 Glu Val Tyr Gly Asp Thr Pro Glu Trp
185 1 5
187 <210> SEQ ID NO: 18
188 <211> LENGTH: 8
189 <212> TYPE: PRT
190 <213> ORGANISM: Artificial Sequence
191 <220> FEATURE:
192 <223> OTHER INFORMATION: Peptide Derived from Human Papillomavirus
193 <400> SEQUENCE: 18
194 Phe Ile Val Asn Asp Asn Asp Tyr
195 1 5
197 <210> SEQ ID NO: 19
198 <211> LENGTH: 9
199 <212> TYPE: PRT
200 <213> ORGANISM: Artificial Sequence
201 <220> FEATURE:
202 <223> OTHER INFORMATION: Peptide Derived from Human Papillomavirus
203 <400> SEQUENCE: 19
204 Phe Leu Gln Gly Ser Val Ile Cys Phe
205 1 5
207 <210> SEQ ID NO: 20
208 <211> LENGTH: 9
209 <212> TYPE: PRT
210 <213> ORGANISM: Artificial Sequence

RAW SEQUENCE LISTING

DATE: 01/17/2003

PATENT APPLICATION: US/09/641,528A

TIME: 10:57:53

Input Set : N:\Crf4\01162003\I641528.raw

Output Set: N:\CRF4\01172003\I641528A.raw

211 <220> FEATURE:
212 <223> OTHER INFORMATION: Peptide Derived from Human Papillomavirus
213 <400> SEQUENCE: 20
214 Phe Leu Arg Tyr Gln Gly Val Glu Phe
215 1 5
217 <210> SEQ ID NO: 21
218 <211> LENGTH: 8
219 <212> TYPE: PRT
220 <213> ORGANISM: Artificial Sequence
221 <220> FEATURE:
222 <223> OTHER INFORMATION: Peptide Derived from Human Papillomavirus
223 <400> SEQUENCE: 21
224 Phe Leu Thr Ala Leu Lys Arg Phe
225 1 5
227 <210> SEQ ID NO: 22
228 <211> LENGTH: 11
229 <212> TYPE: PRT
230 <213> ORGANISM: Artificial Sequence
231 <220> FEATURE:
232 <223> OTHER INFORMATION: Peptide Derived from Human Papillomavirus
233 <400> SEQUENCE: 22
234 Phe Met Ser Phe Leu Thr Ala Leu Lys Arg Phe
235 1 5 10
237 <210> SEQ ID NO: 23
238 <211> LENGTH: 8
239 <212> TYPE: PRT
240 <213> ORGANISM: Artificial Sequence
241 <220> FEATURE:
242 <223> OTHER INFORMATION: Peptide Derived from Human Papillomavirus
243 <400> SEQUENCE: 23
244 Phe Ser Glu Leu Val Arg Pro Phe
245 1 5
247 <210> SEQ ID NO: 24
248 <211> LENGTH: 9
249 <212> TYPE: PRT
250 <213> ORGANISM: Artificial Sequence
251 <220> FEATURE:
252 <223> OTHER INFORMATION: Peptide Derived from Human Papillomavirus
253 <400> SEQUENCE: 24
254 Phe Thr Phe Pro Asn Glu Phe Pro Phe
255 1 5
257 <210> SEQ ID NO: 25
258 <211> LENGTH: 8
259 <212> TYPE: PRT
260 <213> ORGANISM: Artificial Sequence
261 <220> FEATURE:
262 <223> OTHER INFORMATION: Peptide Derived from Human Papillomavirus
263 <400> SEQUENCE: 25
264 Phe Val Asn Ser Lys Ser His Phe

RAW SEQUENCE LISTING ERROR SUMMARY
PATENT APPLICATION: US/09/641,528A

DATE: 01/17/2003
TIME: 10:57:54

Input Set : N:\Crf4\01162003\I641528.raw
Output Set: N:\CRF4\01172003\I641528A.raw

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

Seq#:46478; Xaa Pos. 1,2,3
Seq#:46515; Xaa Pos. 1,2,3
Seq#:46537; Xaa Pos. 1,2,3
Seq#:46552; Xaa Pos. 1,2,3
Seq#:46553; Xaa Pos. 1
Seq#:46639; Xaa Pos. 1,2,3
Seq#:46845; Xaa Pos. 1,2
Seq#:46896; Xaa Pos. 1,2,3
Seq#:46912; Xaa Pos. 1
Seq#:47013; Xaa Pos. 1,2,3
Seq#:47014; Xaa Pos. 1,2
Seq#:47238; Xaa Pos. 1,2,3
Seq#:47239; Xaa Pos. 1,2
Seq#:47282; Xaa Pos. 1,2,3
Seq#:47309; Xaa Pos. 1,2,3
Seq#:47324; Xaa Pos. 1,2,3
Seq#:47399; Xaa Pos. 1,2,3
Seq#:47565; Xaa Pos. 1,2,3
Seq#:47618; Xaa Pos. 1,2,3
Seq#:47619; Xaa Pos. 1,2
Seq#:47620; Xaa Pos. 1
Seq#:47675; Xaa Pos. 1,2,3
Seq#:47690; Xaa Pos. 1,2,3
Seq#:47770; Xaa Pos. 1,2,3
Seq#:47938; Xaa Pos. 1,2,3
Seq#:48003; Xaa Pos. 1,2,3
Seq#:48018; Xaa Pos. 1,2,3
Seq#:48110; Xaa Pos. 1,2,3
Seq#:48111; Xaa Pos. 1,2
Seq#:48182; Xaa Pos. 1,2
Seq#:48242; Xaa Pos. 1,2,3
Seq#:48259; Xaa Pos. 1,2,3
Seq#:48260; Xaa Pos. 1
Seq#:48349; Xaa Pos. 1,2,3
Seq#:48350; Xaa Pos. 1,2
Seq#:51503; Xaa Pos. 1,5,6,8,9
Seq#:51504; Xaa Pos. 1,3,5,6,7

Invalid Line Length:

The rules require that a line not exceed 72 characters in length. This includes spaces.

Seq#:1; Line(s) 7

VERIFICATION SUMMARY

DATE: 01/17/2003

PATENT APPLICATION: US/09/641,528A

TIME: 10:57:54

Input Set : N:\Crf4\01162003\I641528.raw

Output Set: N:\CRF4\01172003\I641528A.raw

L:464798 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:46478 after pos.:0
L:465172 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:46515 after pos.:0
L:465396 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:46537 after pos.:0
L:465550 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:46552 after pos.:0
L:465564 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:46553 after pos.:0
L:466428 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:46639 after pos.:0
L:468492 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:46845 after pos.:0
L:469006 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:46896 after pos.:0
L:469170 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:46912 after pos.:0
L:470184 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:47013 after pos.:0
L:470198 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:47014 after pos.:0
L:472442 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:47238 after pos.:0
L:472456 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:47239 after pos.:0
L:472890 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:47282 after pos.:0
L:473164 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:47309 after pos.:0
L:473318 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:47324 after pos.:0
L:474072 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:47399 after pos.:0
L:475736 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:47565 after pos.:0
L:476270 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:47618 after pos.:0
L:476284 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:47619 after pos.:0
L:476298 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:47620 after pos.:0
L:476852 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:47675 after pos.:0
L:477006 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:47690 after pos.:0
L:477810 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:47770 after pos.:0
L:479494 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:47938 after pos.:0
L:480148 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:48003 after pos.:0
L:480302 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:48018 after pos.:0
L:481226 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:48110 after pos.:0
L:481240 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:48111 after pos.:0
L:481954 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:48182 after pos.:0
L:482558 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:48242 after pos.:0
L:482732 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:48259 after pos.:0
L:482746 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:48260 after pos.:0
L:483640 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:48349 after pos.:0
L:483654 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:48350 after pos.:0
L:515198 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:51503 after pos.:0
L:515216 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:51504 after pos.:0